Literature DB >> 24790908

Distribution of serotypes and antibiotic susceptibility patterns among invasive pneumococcal diseases in Saudi Arabia.

Yazeed A Al-Sheikh, Yazeed A Al-Sherikh1, Lakshmana K Gowda2, M Marie Mohammed Ali2, James John3, Dabwan Khaled Homoud Mohammed2, Pradeep Chikkabidare Shashidhar2.   

Abstract

BACKGROUND: Streptococcus pneumoniae causes life-threatening infections such as meningitis, pneumonia, and febrile bacteremia, particularly in young children. The increasing number of drug-resistant isolates has highlighted the necessity for intervening and controlling disease. To achieve this, information is needed on serotype distribution and patterns of antibiotic resistance in children.
METHODS: All cases of invasive pneumococcal disease (IPD) in children aged less than 15 yr recorded at King Khalid University Hospital, King Saud University, Riyadh, Saudi Arabia, were reviewed for serotyping and antibiotic susceptibility. Isolates were collected from 78 consecutive patients with IPD between 2009 and 2012. All collected isolates were subjected to serotyping by co-agglutination, sequential multiplex PCR, and single PCR sequetyping as previously described.
RESULTS: The most frequently isolated IPD serotypes were 23F, 6B, 19F, 18C, 4, 14, and 19A, which are listed in decreasing order and cover 77% of total isolates. The serotype coverage for the pneumococcal conjugate vaccine (PCV)7, PCV10, and PCV13 was 77%, 81%, and 90%, respectively. Results from sequential multiplex PCR agreed with co-agglutination results. All serotypes could not be correctly identified using single PCR sequetyping. Minimum inhibitory concentration showed that 50 (64%) isolates were susceptible to penicillin, whereas 70 (90%) isolates were susceptible to cefotaxime.
CONCLUSIONS: The most common pneumococcal serotypes occur with frequencies similar to those found in countries where the PCV has been introduced. The most common serotypes in this study are included in the PCVs. Addition of 23A and 15 to the vaccine would improve the PCV performance in IPD prevention.

Entities:  

Keywords:  Pneumococcal conjugate vaccine; Pneumococcus; Serotype; Vaccination

Mesh:

Substances:

Year:  2014        PMID: 24790908      PMCID: PMC3999319          DOI: 10.3343/alm.2014.34.3.210

Source DB:  PubMed          Journal:  Ann Lab Med        ISSN: 2234-3806            Impact factor:   3.464


  19 in total

1.  Serotyping Streptococcus pneumoniae by multiplex PCR.

Authors:  D A Brito; M Ramirez; H de Lencastre
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

2.  Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates.

Authors:  Rekha Pai; Robert E Gertz; Bernard Beall
Journal:  J Clin Microbiol       Date:  2006-01       Impact factor: 5.948

3.  Genetic basis for the new pneumococcal serotype, 6C.

Authors:  In Ho Park; Saeyoung Park; Susan K Hollingshead; Moon H Nahm
Journal:  Infect Immun       Date:  2007-06-18       Impact factor: 3.441

4.  Sequential multiplex PCR for determining capsular serotypes of pneumococci recovered from Brazilian children.

Authors:  Cícero A Dias; Lúcia Martins Teixeira; Maria da Glória Carvalho; Bernard Beall
Journal:  J Med Microbiol       Date:  2007-09       Impact factor: 2.472

5.  Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.

Authors:  W P Hausdorff; J Bryant; P R Paradiso; G R Siber
Journal:  Clin Infect Dis       Date:  2000-01       Impact factor: 9.079

6.  Beta-lactam and macrolide resistance and serotype distribution among Streptococcus pneumoniae isolates from Saudi Arabia.

Authors:  S I Fouda; A A Kadry; A M Shibl
Journal:  J Chemother       Date:  2004-12       Impact factor: 1.714

7.  Accuracy of phenotypic and genotypic testing for identification of Streptococcus pneumoniae and description of Streptococcus pseudopneumoniae sp. nov.

Authors:  Judy C Arbique; Claire Poyart; Patrick Trieu-Cuot; Gilles Quesne; Maria da Glória S Carvalho; Arnold G Steigerwalt; Roger E Morey; Delois Jackson; Ross J Davidson; Richard R Facklam
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

8.  Serotyping of Streptococcus pneumoniae by coagglutination with 12 pooled antisera.

Authors:  M K Lalitha; K Thomas; R S Kumar; M C Steinhoff
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

Review 9.  Pneumococcal vaccination of older adults: conjugate or polysaccharide?

Authors:  David S Fedson; Martin J Guppy
Journal:  Hum Vaccin Immunother       Date:  2013-05-31       Impact factor: 3.452

10.  Streptococcus pneumoniae serotypes/serogroups causing invasive disease in Riyadh, Saudi Arabia: extent of coverage by pneumococcal vaccines.

Authors:  Abdulrahman Al-Mazrou; Kingsley Twum-Danso; Fahad Al Zamil; Abdelmageed Kambal
Journal:  Ann Saudi Med       Date:  2005 Mar-Apr       Impact factor: 1.526

View more
  3 in total

1.  The Saudi Thoracic Society pneumococcal vaccination guidelines-2016.

Authors:  N S Alharbi; A M Al-Barrak; M S Al-Moamary; M O Zeitouni; M M Idrees; M O Al-Ghobain; A A Al-Shimemeri; Mohamed S Al-Hajjaj
Journal:  Ann Thorac Med       Date:  2016 Apr-Jun       Impact factor: 2.219

2.  Comparison of sequential multiplex PCR, sequetyping and whole genome sequencing for serotyping of Streptococcus pneumoniae.

Authors:  Florian Mauffrey; Éric Fournier; Walter Demczuk; Irene Martin; Michael Mulvey; Christine Martineau; Simon Lévesque; Sadjia Bekal; Marc-Christian Domingo; Florence Doualla-Bell; Jean Longtin; Brigitte Lefebvre
Journal:  PLoS One       Date:  2017-12-13       Impact factor: 3.240

3.  The Emergence of Invasive Streptococcus pneumoniae Serotype 24F in Lebanon: Complete Genome Sequencing Reveals High Virulence and Antimicrobial Resistance Characteristics.

Authors:  Lina Reslan; Marc Finianos; Ibrahim Bitar; Mohamad Bahij Moumneh; George F Araj; Alissar Zaghlout; Celina Boutros; Tamima Jisr; Malak Nabulsi; Gilbert Kara Yaccoub; Monzer Hamze; Marwan Osman; Elie Bou Raad; Jaroslav Hrabak; Ghassan M Matar; Ghassan Dbaibo
Journal:  Front Microbiol       Date:  2021-02-19       Impact factor: 5.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.